Top 10 African countries with highest French Schengen visa applications
France has emerged as the most popular Schengen country for visa applicants in 2024, surpassing traditional destinations like the UK, Canada, Italy, and the US.
France has become the primary Schengen visa destination in 2024, surpassing traditional countries such as the UK and Italy.
Increased visa applications from Africa, particularly North and West African nations, highlight strong ties between France and the continent.
Over 1.36 million applications were from African countries, with Algeria, Tunisia, and Morocco being the leading contributors.
France received over 1.36 million visa applications from Africa, out of a global total of 3 million, marking a 17% increase from the previous year.
The surge in visa applications highlights France's enduring ties with many African nations, driven by shared history, language, and culture, as well as substantial diaspora communities in France and efficient visa procedures.
For many applicants, family connections, educational pursuits, and business relationships continue to fuel strong interest in France
Based on a recent data from Travelobiz, the following are the top 10 African nationalities that submitted applications for French Schengen visas in 2024
Country Total Schengen Applications Application to France % to France
Morocco 606,800 282,153 46.5%
Algeria 544, 634 352,295 64.7%
Tunisia 177,951 106,617 59.9%
Ivory Coast 77,385 62,786 81.1%
Nigeria 111,201 55,833 50.2%
Senegal 72,412 36, 323 50.1%
Cameroon 51,679 31, 349 60.6%
South Africa 193,768 30,304 15.6%
DRC 25,774 24,291 94.2%
Gabon 18, 395 16,913 91.9%
total: 998,864 total: 53%
North and West Africa Lead Applications
The Data above indicates that countries in North and West Africa accounted for the bulk of applications. Algeria, Tunisia, Morocco, Senegal, and Ivory Coast were among the top countries whose nationals preferred France over other Schengen destinations.
Algeria accounted for over 540,000 applications, with nearly 65% directed to France.
Tunisia and Morocco followed closely, with significant proportions of their Schengen applications also headed for France.
Sub-Saharan Africa demonstrated a strong trend toward France. Nations like Gabon, Benin, and Togo channeled over 90% of their Schengen applications to France, while countries like the Ivory Coast, Guinea, and Cameroon also showed a strong preference.
Remarkably, Djibouti, Chad, and the Central African Republic exclusively applied for French Schengen visas, suggesting a distinct cultural or diplomatic connection.
Notably, The data confirms France's status as the gateway to Europe for African travelers, driven by long-standing relationships and present-day opportunities. As bilateral ties continue to grow, the country is expected to remain Africa's leading Schengen destination well into 2025 and beyond.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
42 minutes ago
- Business Wire
CARMAT Announces the First Commercial Implants of Its Aeson® Artificial Heart Outside the European Union
PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today announces the first implants of its Aeson® artificial heart in a commercial set-up, outside the European Union (EU). Two implants of Aeson® artificial heart were performed during the week commencing May 26, 2025 in Israel. The first one was carried out at Hadassah Ein Kerem Hospital in Jerusalem by a team led by Pr Offer Amir, Pr Rabea Asleh and Dr Amit Korach, respectively director of the Heart Institute, director of heart failure unit and director of the cardiac surgery department at Hadassah Medical Center. The second one was carried out at Sheba Medical Center in Ramat Gan (Tel Aviv), by a team led by Dr Jeff Morgan, Dr Leonid Sternik, Dr Alex Fardman and Dr Eyal Nachum, respectively head of mechanical support unit, director of cardiac surgery department, heart failure cardiologist and cardiac transplant surgeon. Those are the first Aeson® implants made in a commercial set-up outside the European Union. These implants bring to 5 the total number of countries 1 where commercial implants have been performed so far. They confirm the trust placed in the device by healthcare professionals, and the growing interest in the therapy. About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson ® artificial heart. The Company's ambition is to make Aeson ® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson ® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson ® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson ® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company's current cash runway is limited to mid-June 2025 (excluding the flexible equity financing line entered into with IRIS, which was announced on March 27, 2025). The Company is also subject to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the pace and results of ongoing or planned clinical trials, technological evolution and competitive environment, regulatory changes, industrial risks, and all risks associated with the Company's growth management. The Company's forward-looking statements mentioned in this press release may not be achieved due to these elements or other risk factors and uncertainties, whether unknown or not considered material and specific by the Company as of today. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA).
Business Insider
an hour ago
- Business Insider
10 rich countries non-committal on Zimbabwe's $2.6b bridge financing appeal
Zimbabwe is yet to secure any firm pledges of financial support from the 10 countries it appealed to in its ongoing bid to settle long-standing debt arrears. Zimbabwe is actively seeking financial support from 10 nations to address its $21 billion debt burden. The country has been unable to access global financial markets since its default in 1999. Zimbabwe has requested $2.6 billion in bridge financing to address debts to international lenders. Zimbabwe is yet to secure any firm pledges of financial support from the 10 countries it appealed to in its ongoing bid to settle long-standing debt arrears. The southern African nation is burdened with a $21 billion debt, which has shut it out of global financial markets since it defaulted in 1999, according to Bloomberg. According to Finance Minister Mthuli Ncube, he had sent letters to Algeria, Brazil, China, France, Germany, Italy, Japan, South Africa, the United Arab Emirates, and the UK, requesting $2.6 billion in bridge financing to help settle debts owed to major multilateral lenders, including the World Bank, the European Investment Bank, and the African Development Bank. However, responses from the countries Zimbabwe approached for debt relief have been mixed. "Some of them are very warm, some of them not so warm. You will get a varied response,' he said. One of the major hurdles to securing the bridge financing is that seven of the countries he contacted, including China and Germany, are already creditors to Zimbabwe. Collective support needed Given the large amount of funding Zimbabwe is seeking, it's unlikely that a single nation will step in as a sponsor. Ncube stressed that it would require a collective effort of at least three countries. He also noted that Zimbabwe may explore other avenues to raise funds for debt repayment, including asset sales, though he did not offer specifics.
Business Upturn
3 hours ago
- Business Upturn
Manchester City makes transfer plans ahead of the Club World Cup
Manchester City have made some transfer plans ahead of the Club World Cup which is to be started this month. By Ravi Kumar Jha Published on June 2, 2025, 08:32 IST Manchester City have made some transfer plans ahead of the Club World Cup which is to be started this month. As the transfer window has been officially opened, so City are trying hard to get two deals done. Rayan Cherki from Lyon FC and Reijnders from AC Milan are what the Blues are looking for. They want both these player to join the squad before the Club World Cup starts. City are also in good talks with Lyon over Cherki's deal and the agreement is likely to be signed soon. With the summer transfer window officially open and the FIFA Club World Cup fast approaching, Manchester City are wasting no time in reinforcing their squad. The reigning European champions have set their sights on two promising talents — Rayan Cherki of Lyon and Tijjani Reijnders of AC Milan — as they prepare for the prestigious tournament kicking off later this month. Sources close to the club suggest that City are in advanced talks with Lyon for the highly-rated French midfielder Cherki. The 20-year-old, known for his flair and creativity, has long been on the radar of top European clubs, and City appear confident of sealing the deal soon. Negotiations are said to be progressing positively, with an agreement likely to be signed in the coming days. Meanwhile, City are also pushing hard to secure the services of Dutch midfielder Reijnders from AC Milan. The 25-year-old impressed in his debut Serie A season and is seen as a player who can add depth and versatility to Pep Guardiola's midfield. Ravi kumar jha is an undergraduate student in Bachelor of Arts in Multimedia and Mass Communication. A media enthusiast who has a strong hold on communication and he also has a genuine interest in sports. Ravi is currently working as a journalist at
